<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622957</url>
  </required_header>
  <id_info>
    <org_study_id>PURITY - Protocol 2</org_study_id>
    <nct_id>NCT03622957</nct_id>
  </id_info>
  <brief_title>Association Between Phthalates Exposure and Renal Function Impairment in TYpe 2 Diabetes</brief_title>
  <acronym>PURITY-2</acronym>
  <official_title>Exploring the Association Between Phthalates Exposure, Measured Through Their Urinary Metabolites, and Renal Function Impairment in Individuals With TYpe 2 Diabetes - Protocol 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto di Fisiologia Clinica CNR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global incidence of diabetic nephropathy (DN) is increasing, with no appreciable
      reduction in the percent of patients progressing toward end stage renal disease (ESRD) and
      dialysis (Tuttle et al, 2014, Winocour et al, 2018). Therefore, identification of modifiable
      risk factors and early biomarkers of progressive decline in kidney function is an urgent
      clinical need. Phthalates are environmental and dietary contaminants with a various array of
      use that are identified in many consumer and industrial products; among them,
      di-(2-ethylhexyl) phthalate (DEHP) and its metabolites (mono 2-ethylhexyl phthalate (MEHP),
      5OH-MEHP (MEHHP) and 5oxo-MEHP (MEOHP)) are widely used (Kato et al 2004, Braun et al, 2013).
      They partially distribute to the human tissues and their urinary and serum levels are
      directly related; therefore, urinary concentration of phthalates is commonly used as proxy of
      their exposure in humans (Kato et al 2004).

      While the association between phthalates exposure and development of T2D is currently being
      explored (Dong et al 2017, Dales et al, 2018), little is known about their role in DN. Recent
      observations show that DEHP and its metabolites are associated with a higher prevalence of
      low-grade albuminuria and in children exposed to higher phthalates concentrations (Trasande
      et al, 2014, Wu et al, 2018), however such association has yet to be verified in adults. The
      environmental ubiquity of the phthalates enhances the importance of investigating the
      potential relation between their exposure and different degrees of renal function. (Kato et
      al 2004, Kataria et al, 2015).

      Given this premise, the investigators will explore this potential association in a population
      of subjects with T2D consecutively referring to the outpatient diabetes clinic in Santa
      Chiara Hospital, Pisa, enrolled on a volunteer basis. During their routine visit at Santa
      Chiara Hospital outpatient diabetes clinic participants will provide the results of blood
      tests prescribed as per standard clinical practice along with a first morning, overnight
      fasting, urine sample collected in a phthalates-free container.

      The investigators will record the participants' clinical history, physical examination and
      anthropometric measurements, will measure their renal function, evaluated by eGFR (calculated
      with the CDK-EPI formula), albumin excretion, fasting glucose, HbA1c%, and the exposure to
      phthalates, assessed by total concentrations of MEHP, MEOHP, MEHHP and adjusted for urinary
      creatinine. In this way, the investigators aim to point out the relationship of urinary
      phthalates with higher degrees of albuminuria and/or lower eGFR after adjustment for all
      potential confounders, including therapies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2018</start_date>
  <completion_date type="Anticipated">September 3, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Phthalates exposure [ug/g]</measure>
    <time_frame>Single routine clinical visit</time_frame>
    <description>Concentrations of metabolites of DEHP [ug/ml] in a first morning spot urine sample (obtained during clinical visit) measured by ultra-HPLC coupled with electrospray ionization/quadrupole time-of-flight MS and then normalized for urinary creatinine [g/ml].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albuminuria [mg/g]</measure>
    <time_frame>Single routine clinical visit</time_frame>
    <description>Grade of albuminuria measured by albuminuria/creatininuria ratio [mg/g] in a first morning spot urine sample (obtained during clinical visit).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular Filtration Rate [ml/min/1.73m2]</measure>
    <time_frame>Single routine clinical visit</time_frame>
    <description>GFR measured by eGFR (calculated with CDK-EPI formula). Creatinine [mg/dL] is measured in a serum sample (obtained during clinical visit). Physiological parameters (age, sex, race) are obtained during clinical visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CV Events (Yes/No)</measure>
    <time_frame>Single routine clinical visit</time_frame>
    <description>History of cardiovascular events (Non fatal: Acute Myocardial infarction, Unstable Angina, Stroke), evaluated by clinical interview during routine clinical visit.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Albuminuria</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetes subjects</arm_group_label>
    <description>Type 2 diabetes subjects consecutively referring to Santa Chiara, Pisa diabetes outpatients clinic</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      First morning spot urine sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetes individuals referring to our outpatient clinics
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18-85 years, T2D diagnosis, T2D duration &gt;6 months,

        Exclusion Criteria:

        occurring acute clinical conditions, eGFR &lt;15 ml/min/1.73m2, BMI &gt; 40 Kg/m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Solini, Associate Professor, MD, PhD</last_name>
    <phone>+39 050993482</phone>
    <email>anna.solini@med.unipi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandro Mengozzi, MD</last_name>
    <phone>+ 39050993640</phone>
    <email>alessandro.mengozzi@medmcs.unipi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Solini, Associate Professor, MD, PhD</last_name>
      <phone>+39 050993482</phone>
      <email>anna.solini@med.unipi.it</email>
    </contact>
    <contact_backup>
      <last_name>Alessandro Mengozzi, MD</last_name>
      <phone>+39 050993640</phone>
      <email>alessandro.mengozzi@medmcs.unipi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Anna Solini, Associate Professor, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amalia Gastaldelli, Associate Professor, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Mengozzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct;37(10):2864-83. doi: 10.2337/dc14-1296.</citation>
    <PMID>25249672</PMID>
  </reference>
  <reference>
    <citation>Winocour PH. Diabetes and chronic kidney disease: an increasingly common multi-morbid disease in need of a paradigm shift in care. Diabet Med. 2018 Mar;35(3):300-305. doi: 10.1111/dme.13564. Epub 2018 Jan 8. Review.</citation>
    <PMID>29247554</PMID>
  </reference>
  <reference>
    <citation>Kato K, Silva MJ, Reidy JA, Hurtz D 3rd, Malek NA, Needham LL, Nakazawa H, Barr DB, Calafat AM. Mono(2-ethyl-5-hydroxyhexyl) phthalate and mono-(2-ethyl-5-oxohexyl) phthalate as biomarkers for human exposure assessment to di-(2-ethylhexyl) phthalate. Environ Health Perspect. 2004 Mar;112(3):327-30.</citation>
    <PMID>14998748</PMID>
  </reference>
  <reference>
    <citation>Braun JM, Sathyanarayana S, Hauser R. Phthalate exposure and children's health. Curr Opin Pediatr. 2013 Apr;25(2):247-54. doi: 10.1097/MOP.0b013e32835e1eb6. Review.</citation>
    <PMID>23429708</PMID>
  </reference>
  <reference>
    <citation>Dong R, Zhao S, Zhang H, Chen J, Zhang M, Wang M, Wu M, Li S, Chen B. Sex Differences in the Association of Urinary Concentrations of Phthalates Metabolites with Self-Reported Diabetes and Cardiovascular Diseases in Shanghai Adults. Int J Environ Res Public Health. 2017 Jun 5;14(6). pii: E598. doi: 10.3390/ijerph14060598.</citation>
    <PMID>28587233</PMID>
  </reference>
  <reference>
    <citation>Dales RE, Kauri LM, Cakmak S. The associations between phthalate exposure and insulin resistance, β-cell function and blood glucose control in a population-based sample. Sci Total Environ. 2018 Jan 15;612:1287-1292. doi: 10.1016/j.scitotenv.2017.09.009. Epub 2017 Sep 8.</citation>
    <PMID>28898934</PMID>
  </reference>
  <reference>
    <citation>Trasande L, Sathyanarayana S, Trachtman H. Dietary phthalates and low-grade albuminuria in US children and adolescents. Clin J Am Soc Nephrol. 2014 Jan;9(1):100-9. doi: 10.2215/CJN.04570413. Epub 2013 Oct 31.</citation>
    <PMID>24178978</PMID>
  </reference>
  <reference>
    <citation>Wu CF, Hsiung CA, Tsai HJ, Tsai YC, Hsieh HM, Chen BH, Wu MT. Interaction of melamine and di-(2-ethylhexyl) phthalate exposure on markers of early renal damage in children: The 2011 Taiwan food scandal. Environ Pollut. 2018 Apr;235:453-461. doi: 10.1016/j.envpol.2017.12.107. Epub 2018 Jan 6.</citation>
    <PMID>29310089</PMID>
  </reference>
  <reference>
    <citation>Kataria A, Trasande L, Trachtman H. The effects of environmental chemicals on renal function. Nat Rev Nephrol. 2015 Oct;11(10):610-25. doi: 10.1038/nrneph.2015.94. Epub 2015 Jun 23. Review.</citation>
    <PMID>26100504</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Anna Solini</investigator_full_name>
    <investigator_title>Associate Professor, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

